An elegant clinical study on 553 adults with recent-onset T1D combined mild immunosuppression in the form of anti-IL-21 blockade with GLP-1RA (liraglutide) aimed at improving β-cell function and preventing apoptosis (von Herrath et al, 2021). The gene discussed is IL21; the disease is type 1 diabetes mellitus.